| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Electra Therapeutics, Inc.
13G
ETRA · 284825106
|
6.0% |
9/28/2026
Event 9/21/2026
|
|||
| LSP 7 Cooperatief U.A. | 6.0% | ||||
| LSP 7 Management B.V. | 6.0% | ||||
|
Oculis Holding AG
13G/A
Amendment 2
OCS · H5870P102
|
11.8% |
4/29/2026
Event 3/31/2026
|
|||
| LSP 7 Cooperatieve U.A. | 11.8% | ||||
| LSP 7 Management B.V. | 11.8% | ||||
|
Evommune, Inc.
13D/A
Amendment 1
EVMN · 30054Y107
|
14.7% |
2/19/2026
Event 2/12/2026
|
|||
| LSP 7 Cooperatieve U.A. | 14.7% | ||||
| LSP 7 Management B.V. | 14.7% | ||||
|
AgomAb Therapeutics NV
13D
AGMB · 00860C102
|
10.6% |
2/17/2026
Event 2/9/2026
|
|||
| LSP 7 Cooperatieve U.A. | 10.6% | ||||
| LSP 7 Management B.V. | 10.6% | ||||
|
Evommune, Inc.
13D
EVMN · 30054Y107
|
15.7% |
11/14/2025
Event 11/7/2025
|
|||
| LSP 7 Cooperatieve U.A. | 15.7% | ||||
| LSP 7 Management B.V. | 15.7% | ||||
|
Oculis Holding AG
13G/A
Amendment 1
OCS · H5870P102
|
13.8% |
2/12/2025
Event 12/31/2024
|
|||
| LSP 7 Cooperatieve U.A. | 13.8% | ||||
| LSP 7 Management B.V. | 13.8% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.